CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer

Hideki Enokida,1,4 Hiroaki Shiina,1,2 Mikio Igawa,2 Tatsuya Ogishima,1 Toshifumi Kawakami,1 William W. Bassett,1 Jason W. Anast,1 Long-Cheng Li,1 Shinji Urakami,2 Masaharu Terashima,2 Mukesh Verma,3 Motoshi Kawahara,4 Masayuki Nakagawa,3 Christopher J. Kane,1 Peter R. Carroll,1 and Rajvir Dahiya1

1Department of Urology, University of California, San Francisco, and Veterans Affairs Medical Center, San Francisco, California; 2Department of Urology and Biochemistry, Shimane University, Izumo, Japan; 3Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Urology, Kagoshima University, Kagoshima, Japan

ABSTRACT

Multidrug resistance 1 (MDR1) gene encodes for P-glycoprotein (P-gp), a Mr 170,000 transmembrane calcium-dependent efflux pump that is inactivated in prostate cancer. We hypothesize that inactivation of the MDR1 gene through CpG methylation contributes to the pathogenesis and progression of prostate cancer. To test this hypothesis, CpG methylation status of the MDR1 promoter and its correlation with clinicopathological findings were evaluated in 177 prostate cancer samples and 69 benign prostate hypertrophy (BPH) samples. Cellular proliferation index and apoptotic index were determined by proliferating cell nuclear antigen (PCNA) and single-strand DNA immunostaining, respectively. After 5-aza-2'-deoxycytidine treatment, increased expression of MDR1 mRNA transcript was found in prostate cancer cell lines (DU145, DuPro, and ND1). MDR1 methylation frequency was significantly higher in prostate cancer samples compared with BPH samples (54.8 versus 11.6%, respectively, P < 0.001). Logistic regression analysis revealed that PC patients are 11.5 times more likely to have MDR1 methylation than BPH patients (95% confidence interval 4.87–27.0) and that MDR1 methylation is independent of the age. Significant correlation of MDR1 methylation was observed with high pT category (P < 0.001), high Gleason sum (P = 0.008), high preoperative prostate-specific antigen (P = 0.001), and advancing pathological features. In addition, PCNA-labeling index were significantly higher in methylation-specific PCR (MSP)-positive than in MSP-negative prostate cancer samples (P = 0.048). In contrast, no significant difference in apoptotic index was found between MSP-positive and -negative prostate cancer samples. These findings suggest that CpG hypermethylation of MDR1 promoter is a frequent event in prostate cancer and is related to disease progression via increased cell proliferation in prostate cancer cells.

INTRODUCTION

Prostate cancer is one of the most common malignancies among men (1, 2). In organ-confined prostate cancer, treatments such as radical prostatectomy (1), radiotherapy (2), and chemotherapy (3) are effective. However, multiple drug resistance often develops in patients with advanced disease. Multidrug resistance 1 (MDR1) gene encodes for P-glycoprotein (P-gp), a Mr 170,000 transmembrane calcium-dependent efflux pump, which is expressed in various tissues (4–6). Aberrant expression of P-gp is associated with various cancers. Recent studies have shown that hypermethylation of normally unmethylated CpG dinucleotides (CpG islands) located in the promoter regions is involved in gene silencing at the transcriptional level (7, 8).

In some cancers, one of the mechanisms underlying down-regulation of MDR1 is thought to be CpG hypermethylation of the MDR1 promoter (9–11). Recent publications have indicated another functional role of P-gp as a marker for disease progression, in addition to the conventional role as a drug resistance marker (12–16). In hepatocellular carcinoma and osteosarcoma, it has been demonstrated that the frequency of P-gp overexpression is higher in patients with localized disease than in metastatic diseases (12, 13). It is not known whether expression of P-gp is associated with disease progression in prostate cancer (14–16).

We hypothesize that inactivation of MDR1 genes through CpG methylation is responsible for the pathogenesis and progression of prostate cancer. To address this issue, we analyzed mRNA levels and promoter methylation status of the MDR1 gene in prostate cancer samples and related these findings to clinical and pathological outcomes. In addition, we also evaluated the imbalance between cell proliferation and apoptosis and its association with methylation status of MDR1 promoter in human prostate cancer tissues.

MATERIALS AND METHODS

Tissue Samples. A total of 177 newly diagnosed prostate cancer tissues from radical prostatectomies (136 retropubic and 41 perineal approaches) and 69 pathologically proven benign prostate hypertrophy (BPH) samples from transurethral resection was obtained from Shimane University Hospital (Izumo, Japan). The patients’ background and clinicopathological characteristics are summarized in Table 1. The pathological findings of prostate cancer samples were determined by the general rule for Clinical and Pathological Studies on prostate cancer by the Japanese Urological Association and the Japanese Society of Pathology (17). Our routine diagnostic work-up for prostate cancer includes serum prostate-specific antigen (PSA) level, transrectal ultrasonography, color Doppler ultrasonography, and magnetic resonance imaging, which enable us to speculate more accurate localization of prostate cancer before radical prostatectomy (18). As a control, 10 samples of normal peripheral blood lymphocytes were used.

Tissue Preparations. All of BPH samples and half of each prostate cancer samples were fixed in 10% buffered formalin (pH 7.0) and embedded in paraffin wax. For histological evaluation, 5-μm thick sections were used for H&E staining. The remaining half of each prostate cancer sample was immediately frozen and stored at −80°C for RNA extraction. All of the samples were microscopically dissected and analyzed for methylation. In BPH samples, high-grade prostate intraepithelial neoplasia and cancer were ruled out by microscopically analysis.

Cell Culture. Human prostate cancer cell lines of Du145 and DuPro were obtained from American Type Culture Collection (Manassas, VA). The other human PC cell line, ND1, was developed in our laboratory (19). The media used in this study for Du145, DuPro, and ND1 were RPMI 1640 supplemented with 10% fetal calf solution.

Nuclease Acid Extraction. Genomic DNA from all prostate samples and blood samples was extracted using a commercial kit (Qiagen, Valencia, CA) after microdissection (20) and was precipitated with ethanol. Genomic DNA from cell line samples was extracted with DNazol reagent (Invitrogen-Life Technologies, Inc., Carlsbad, CA). Total RNA was extracted by TRI Reagent (Molecular Research Center, Cincinnati, OH). RNA specimens were stored in aliquots at −80°C before use. The concentration of DNA and RNA was determined by UV spectrophotometry.

Received 1/10/04; revised 6/1/04; accepted 7/6/04.

Grant support: The present study was supported by a VA Merit Review Grant/Research Enhancement Award Program and NIH Grants RO1CA101844, RO1AG21418, and T32DK07790.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Rajvir Dahiya, Professor of Urology, Director of Urology Research Center (112F), University of California San Francisco and Veterans Affairs Medical Center, San Francisco, California; Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland; and Department of Urology, Kagoshima University, Kagoshima, Japan.

5956

©2004 American Association for Cancer Research.
determined by spectrophotometer, and their integrity was checked by gel electrophoresis.

cDNA Preparation and Differential Reverse Transcription-PCR (RT-PCR) of MDR1. RNA, 1 μg, was added to 0.5 μg of oligodeoxymethylidic acid primer (Promega, Madison, WI) and prepared to a final volume of 25 μL. The primer RNA mixture was then combined with 0.25 units of Avian myeloblastosis virus reverse transcriptase (Promega) and 0.5 units of RNase inhibitor. The reverse transcriptase reaction was then carried out at 45°C for 45 min. The cDNA was then incubated at 95°C for 5 min to inactivate the reverse transcriptase. Samples were stored at −20°C until used.

The cDNA samples, 2 μL, were diluted into 20 μL of solution containing 50 mMol/L deoxynucleoside triphosphate, 0.5 units of RedTaq polymerase and PCR reaction buffer provided by the manufacturer (Sigma, St. Louis, MO). For differential RT-PCR between MDR1 and G3PDH, different primer sets of s-G3PDH primers and l-G3PDH primers were used for analysis of prostate cancer cell lines and clinical samples, respectively. For cell lines samples, l-G3PDH-S and l-G3PDH-AS primer concentrations were 50 nmol/L, whereas MDR1-RT-S and MDR1-RT-AS primer concentrations were 250 nmol/L. For clinical samples, s-G3PDH-S and s-G3PDH-AS primer concentrations were 100 nmol/L, whereas MDR1-RT-S and MDR1-RT-AS primer concentrations were 150 nmol/L. The primer sequences and PCR conditions (annealing temperatures, times, and cycle numbers) are shown in Table 2. The PCR products were electrophoresed on 3% agarose gel electrophoresis. The area under the curve (AUC) corresponding to each band was calculated as arbitrary units. For semiquantitative analysis of the amplified products, a suitable PCR primer or reverse Pan-AS primer was performed according to the manufacturers instruction (Applied BioSystems, Foster City, CA).

Immunostaining. Immunostaining of proliferating cell nuclear antigen (PCNA) and single-strand DNA was performed on 5-μm thick consecutive sections obtained from paraffin-embedded materials, using mouse monoclonal antibody for PCNA (clone PC-10, 1:1000 dilution; Dako, Glostrup, Denmark) and single-strand DNA (1:100 dilution; Dako, Kyoto, Japan; ref. 24), respectively. The slides were microwaved for antigen retrieval in citrate buffer [10 mM (pH 6.0)] before incubation of primary antibody. In negative controls, the primary antibody was replaced by a nonimmune serum. 3.3’-Diaminobenzidine (Sigma-Aldrich, St. Louis, MO) was used as the chromogen, and counterstaining was performed using 0.5% hematoxylin.

Statistical Analysis. Relationship between mRNA expression and methylation of the MDR1 promoter in prostate cancer samples was analyzed with the Mann-Whitney U test. The relationship between clinicopathological findings and methylation status of MDR1 was performed using χ2 test, Mann-Whitney U test and logistic regression analysis. P < 0.05 was regarded as statistically significant.

RESULTS

Effects of 5-Aza-dC on MDR1 Gene Expression in Prostate Cancer. At baseline, expression of the MDR1 mRNA transcript was negative in DU145 and ND1 and was weak in DuPro prostate cancer cell lines (Fig. 2). However, after 4 days of treatment with 5-aza-dC, the expression level was significantly increased in DU145 and ND1 cell lines and moderately increased in DuPro cell lines. This data suggests that demethylation (5-aza-dC) restored expression of MDR1 gene in prostate cancer cell lines.

Methylation Status of MDR1 Promoter and MDR1 mRNA Expression in Prostate Clinical Samples. Representative results of MSP and USP assays as well as RT-PCR in prostate cancer samples are shown in Fig. 3. A and B. The prostate cancer samples with positive MSP band (numbers 1, 2, 6, 7, and 8) showed only weak expression of MDR1 mRNA transcript. Interestingly, the other prostate cancer samples with negative MSP band showed strong expression of MDR1 mRNA transcript. No MSP bands were detectable in 10 genomic DNA samples from peripheral blood lymphocytes (Fig. 3D). Fig. 3C shows the typical bisulfite DNA sequencing in prostate cancer samples. In sample number 2, both MSP- and USP-positive bands (Fig. 3A) showed complete or partial methylation at the specific CpG sites. For example, at the CpG sites of −29 and −34 there was a strong “C” and no “T” signal, indicating complete CpG methylation.

Table 1. Clinical characteristics of prostate cancer and benign prostate hypertrophy patients.

<table>
<thead>
<tr>
<th>Prostate cancer</th>
<th>Total number</th>
<th>Median age (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pT category</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>pT2</td>
<td>118</td>
<td></td>
</tr>
<tr>
<td>pT3</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>pT4</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>GS ≤4</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>≥8</td>
<td>33</td>
<td></td>
</tr>
</tbody>
</table>

Preoperative serum PSA <4 22 4–10 80 >10 75

Benign prostate hypertrophy Total number 69 Median age (range) 75 (54–87) yrs

and reverse primers, in which six CpG sites and two SP-1 sites are covered, and corresponding amplified regions are shown in Fig. 1. The forward and reverse primers of each MSP and USP were designed to cover the SP-1 site at their 3′-end because both SP-1 sites are mandatory for the functional MDR1 promoter to be activated (22). For MSP and USP, an initial PCR product was created with universal primers (Pan-S and Pan-AS), followed by a second nested PCR with primers specific for MSP or USP (M-S, M-AS and U-S, and U-AS, respectively). In each assay, absence of DNA template served as negative control. The primer sequences and PCR conditions are shown in Table 2. The obtained MSP and USP products were analyzed on 3% agarose gel electrophoresis. The area under the curve (AUC) corresponding to each band was analyzed using the ImageJ software. We used both visual and percent methylation fraction methylation methods and found that the results are the same. At first, percent methylation of each sample was calculated using the following formula: percent methylation (A) = A(M) × 100/(A(M) + A(U)), where A(M) is AUC of MSP band and A(U) is AUC of USP band (23). We applied percent methylation of 8.5% as cutoff value, which was the average percentage of methylation fraction in 69 BPH samples. Using this criteria, MSP positive was defined as prostate cancer samples with percent methylation fraction of >8.5%, and negative was <8.5%.

Bisulfite DNA Sequencing Analysis. Bisulfite-modified DNA, 1 μL, was amplified using a pair of universal primers (Pan-S and Pan-AS) in a total volume of 20 μL of mixture. The PCR conditions are shown in Table 2. Direct bisulfite DNA sequencing of the PCR products using either forward Pan-S primer or reverse Pan-AS primer was performed according to the manufactures instruction (Applied BioSystems, Foster City, CA).

5 Internet address: http://rsb.info.nih.gov/ij.

6 Internet address: http://itsa.ucsf.edu/~urolab/methprimer.
On the other hand, at the CpG sites of −51, −56, and −59, there was a modest T signal along with a stronger C peak, indicating these CpG sites were partially methylated. In the number 8 prostate cancer sample, where no MSP band was observed (Fig. 3A), all CpG sites of −29, −34, −51, −56, and −59 were completely unmethylated. In our series, positive MSP bands were found in 97 of 177 prostate cancer samples (54.8%). As shown in Fig. 4, relative expression of MDR1 mRNA transcript was significantly lower in the 97 prostate cancer samples with positive MSP than in the remaining 80 cases with negative MSP (P = 0.021).

### Correlation of MDR1 Gene Methylation with Clinicopathological Findings

Ninety-seven of 177 prostate cancer samples (54.8%) showed positive MSP bands, whereas only 8 of 69 BPH samples (11.6%) showed positive MSP bands. On the other hand, the majority of both BPH and prostate cancer samples showed USP bands, although the intensity of USP band was strong in BPH and weak in prostate cancer. The difference in the frequency of MDR1 promoter methylation was significant between prostate cancer and BPH samples (P < 0.001). In the total group of prostate cancer and BPH, there was no correlation between age and methylation. The frequency of MDR1 methylation showed a significant stepwise increase with advancing pathological stage (29% in pT2a, 56% in pT2b, 69% in pT3a, 75% in pT3b, and 100% in pT4; P < 0.001; Fig. 5A). Similarly for Gleason sum (GS), the frequency of MDR1 methylation increased as GS increased (45% in GS < 7, 60% in GS = 7, and 76% in GS > 7; P = 0.008; Fig. 5B). With regard to preoperative PSA, methylation frequency was higher in PSA ≥ 10 ng/ml (66%) than in PSA < 10 ng/ml (47%; P = 0.01; Fig. 5C). As shown in Table 3, no significant association between patient age and MDR1 methylation was found. Logistic regression analysis after age adjustment revealed that pathology (BPH versus prostate cancer) is a significant dependent predictor of MDR1 methylation (P < 0.001), where cases with MDR1 methylation are 11.5 times more likely to have prostate cancer than cases with negative methylation. Fig. 5C shows that there were also significant correlations between MDR1 methylation and capsular invasion (P < 0.001), seminal vesicle involvement (P = 0.007), pN category

### Table 2. Primer sequence and PCR conditions

<table>
<thead>
<tr>
<th>Primer sequence (5'-3')</th>
<th>Product size (bp)</th>
<th>Annealing temperature, time (cycle)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Differential RT-PCR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDR1-RT-S</td>
<td>GAATCTGGAGAAGACATGACG</td>
<td>259</td>
</tr>
<tr>
<td>MDR1-RT-AS</td>
<td>TCCAATTTTGTCACCAATCC</td>
<td></td>
</tr>
<tr>
<td>s-G3PDH-S</td>
<td>GAAGTTGAAAAGTCGAGTTC</td>
<td>226</td>
</tr>
<tr>
<td>s-G3PDH-AS</td>
<td>GAAGATGTTGATGGAGTTTC</td>
<td></td>
</tr>
<tr>
<td>iG3PDH-S</td>
<td>TCCCATCACCATCTCACA</td>
<td>380</td>
</tr>
<tr>
<td>iG3PDH-AS</td>
<td>CATACGCCACAGTTC</td>
<td></td>
</tr>
<tr>
<td>Methylation analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Universal primer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pan-S</td>
<td>GGAAGTTGAGAATATTTTTTGGAAAT</td>
<td>223</td>
</tr>
<tr>
<td>Pan-AS</td>
<td>ACCTCACTCTCTTTAACCTAAAAACC</td>
<td></td>
</tr>
<tr>
<td>MSP primer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M-S</td>
<td>CGAAGGAAATTGATTATTAGTTAATTCGGTCGG</td>
<td>95</td>
</tr>
<tr>
<td>M-AS</td>
<td>ACTCAACCCACGCCCCGACG</td>
<td></td>
</tr>
<tr>
<td>USP primer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>U-S</td>
<td>TGGAGAATTAGTTATTTAGTTAATTTTGTTGG</td>
<td>95</td>
</tr>
<tr>
<td>U-AS</td>
<td>ACTCAACCCACACCCACCAACA</td>
<td></td>
</tr>
</tbody>
</table>

Correlation of MDR1 Gene Methylation with Cell Proliferation and Apoptosis. To investigate the correlation between MDR1 gene methylation and increased cell proliferation and decreased cell apoptosis, PCNA-labeling index and apoptotic index determined by single-strand DNA immunostaining was calculated in each prostate cancer sample. As shown in Fig. 6A, the mean PCNA-labeling index was significantly higher in MSP-positive prostate cancer samples (19.9%) than in MSP-negative prostate cancer samples (8.1%; P = 0.048). On the other hand, no significant difference in the mean apoptotic index was observed between MSP-positive prostate cancer samples (0.60%) and MSP-negative prostate cancer samples (0.52%; Fig. 6B).

Correlation of MDR1 Gene Methylation with Cell Proliferation and Apoptosis. To investigate the correlation between MDR1 gene methylation and increased cell proliferation and decreased cell apoptosis, PCNA-labeling index and apoptotic index determined by single-strand DNA immunostaining was calculated in each prostate cancer sample. As shown in Fig. 6A, the mean PCNA-labeling index was significantly higher in MSP-positive prostate cancer samples (19.9%) than in MSP-negative prostate cancer samples (8.1%; P = 0.048). On the other hand, no significant difference in the mean apoptotic index was observed between MSP-positive prostate cancer samples (0.60%) and MSP-negative prostate cancer samples (0.52%; Fig. 6B).

DISCUSSION

P-gp-mediated multidrug resistance has been extensively investigated (9–16). In prostate cancer, the expression of the MDR1 gene is down-regulated (14–16). However, the mechanism of inactivation of the MDR1 gene and its role in pathogenesis and progression of prostate cancer are not known. In the present study, we investigated the MDR1 gene expression, methylation, cellular proliferation index, and apoptotic index in 177 prostate cancer and 69 BPH samples. We additionally correlated MDR1 gene methylation with clinicopathological findings of prostate cancer.

In the present study, expression of MDR1 mRNA transcript was negative or weak in prostate cancer cell lines. Demethylation with 5-aza-dC treatment restored expression of the MDR1 gene, suggesting
that methylation causes inactivation of the MDR1 gene in prostate cancer. On the basis of this result, we hypothesize that the MDR1 promoter was affected by hypermethylation in human prostate cancer. On the basis of the functional promoter of MDR1 gene (21), we designed the MSP and USP primers, where either forward or reverse primer sequence covered the two SP-1 sites that play an important role in regulating gene transcription (ref. 22; Fig. 1). Ninety-seven of 177 prostate cancer samples (54.8%) showed positive MSP band in which samples expression levels of MDR1 mRNA transcript were significantly reduced in comparison with MSP-negative samples, irrespective of the coexisting USP bands (Figs. 3, A and B, and 4B). When dealing with surgically obtained prostate cancer samples, a major concern appears to be contaminated unmethylated normal cells in the results. Although we used microscopically dissected samples, it is impossible to avoid contamination of normal cells completely because tumor cells are intimately associated both with peripheral blood cells

Fig. 4. Correlation of MDR1 mRNA expression with MDR1 promoter methylation in clinical samples. A, relationship between sample dilution rate (1:1, 1:2, 1:4, 1:8, and 1:16) and densitometric data after logistic conversion. The logistic conversion of band intensity with different dilution rate from the same sample was on the same regression line, indicating PCR amplification at 32 cycles being within the exponential phase. B, correlation of methylation status with mRNA transcript level. Samples with negative MSP bands shows significantly higher expression levels of mRNA transcript than those with MSP-positive bands.

Fig. 5. Correlation of clinicopathological features with methylation frequency of MDR1 promoter. A, methylation frequency of MDR1 increased with higher stage of disease (29% in pT2a, 56% in pT2b, 69% in pT3a, 75% in pT3b, and 100% in pT4). B, methylation frequency of MDR1 increased with higher Gleason sum (45% in GS <7, 60% in GS = 7, and 76% in GS >7). C, there was a strong correlation between methylation frequency of MDR1 and worse clinicopathological findings. For preoperative PSA, methylation frequency was higher in PSA ≥ 10 than in <10 ng/ml (47 and 66%, respectively). Cap, capsular invasion; SV, seminal vesicle involvement; pN, lymph node invasion; ly, lymphatic vessel invasion; and PNI, perineural invasion. N and P correspond to negative and positive, respectively.
and stromal cells such as fibroblasts and endothelial cells. The contamination of normal unmethylated cell populations could provide every CpG site with the same or very close percentage of unmethylation peaks. In the number 8 prostate cancer sample (Fig. 3C), where every CpG site was similar partial methylation, the coexisting USP band could represent contamination with nontumor cells. However, we used 10 genomic DNA samples from peripheral blood lymphocytes (as control), and there were no MSP bands (Fig. 3D). This result indicated that the methylation frequency was not affected by contamination of normal cells. Therefore, CpG hypermethylation of the MDR1 promoter has a strong impact on gene transcription and is one of the mechanisms underlying down-regulation of P-gp expression in human prostate cancer tissues. In addition to higher frequencies of positive MSP in prostate cancer samples than in BPH samples (54.8 versus 11.6%), logistic regression analysis also demonstrated that prostate cancer samples were 11.5 times more likely to have methylated alleles of MDR1 promoter than BPH samples (Table 3). The CpG hypermethylation of the glutathione S-transferase π gene (GSTP1) has been present in BPH (25). Similar epigenetic alteration is plausible to occur in the MDR1 promoter as well as in our series of BPH samples. In colon mucosa, two types of methylation have been postulated: age-related methylation (type A) and cancer-related methylation (type C; ref. 26). Although both prostate cancer and BPH are age-dependent disease, our results strongly suggest that CpG hypermethylation of MDR1 promoter in human prostate is cancer-related methylation (type C) and independent of age.

Several earlier studies have explored whether aberrant expression of the MDR1 gene might be a biomarker for the etiology and progression of various cancers (12, 13, 27, 28). Some investigators reported that overexpression of the MDR1 gene can be an active biomarker for tumor progression in breast and colon cancers (27, 28). Other investigators reported that loss of the MDR1 gene is associated with advanced or metastatic stage in hepatocellular carcinoma and osteosarcoma (12, 13). In prostate cancer, Yegnusubramanian et al. (29) demonstrated a high frequency of MDR1 promoter hypermethylation in prostate cancer patients. In the present study, the CpG hypermethylation of MDR1 promoter showed significant correlation with worse clinicopathological features such as higher pT and pN categories, higher GS, capsular extension, involvements of seminal vesicle, veins and lymphatic vessels, and higher preoperative PSA values. Considering that promoter CpG hypermethylation is a likely mechanism for inactivation of MDR1 gene transcription in human prostate cancer and down-regulation of P-gp expression, MDR1 methylation might characterize biological aggressiveness of prostate cancer. The significance of allelic methylation is not known. In this regard, recent study has shown that monoallelic methylation of p27 promoter was associated with transcriptional silencing in melanoma (30). In this study, we do not know whether promoter methylation occurred because of biallelic or monoallelic event. Additional studies are warranted to investigate the role of allelic methylation in prostate cancer.

The balance between proliferation and apoptosis of prostate cancer cells determines the net growth of prostate cancer. Active involvement of MDR1 gene in cell proliferation has been hypothesized based on the following evidence: (a) an inverse correlation between Ki67 and MDR1 expression in advanced prostate cancer (15); (b) high expression of ki-67 and PCNA in mdr1a double-knockout mice during experimental hepatocarcinogenesis (31); and (c) positive correlation between up-regulation of MDR1 and enhancement in human melanoma metastasis suppressor (KiSS-1) activity (32). On the other hand, recent studies have shown that P-gp is associated with an apoptotic pathway in vitro (33–35). In the present study, we analyzed proliferation activity and apoptosis using PCNA and single-strand DNA immunostaining. In our series, the PCNA-labeling index was significantly higher in MSP-positive samples compared with negative sample (Fig. 6A), whereas there was no correlation of MDR1 methylation with apoptotic index (Fig. 6B). These findings suggest that CpG hypermethylation of MDR1 promoter might be involved in prostate cancer disease progression via increased cellular proliferation but less likely via an inhibition of apoptosis.

Fig. 6. Correlation of immunohistochemistry markers with methylation status of MDR1 promoter. In the series of PC samples, A. The mean number of PCNA-positive cells was significantly higher for MSP-positive samples than that for MSP-negative samples (199 versus 81; P = 0.048). B, there was no significant difference in the mean number of single-strand DNA-positive cells between MSP-positive and -negative samples (6.0 versus 5.2; P = 0.744).
Prostate cancer patients with either Gleason scores of >8 at biopsy, PSA level of >20 ng/ml, or clinical stage of greater than T2 are considered at a higher risk of PSA failure 5 years after definite local therapy (36). In addition, no significant survival benefits have been demonstrated in prostate cancer patients who have undergone neoadjuvant hormonal therapy before radical prostatectomy (37). On the basis of these studies in locally advanced prostate cancer, both local therapy and neoadjuvant hormonal therapy are not sufficient to control and eliminate the prostate cancer cells. Recently, Oh et al. (3) reported that neoadjuvant chemotherapy microscopically conferred cytotoxic effects on prostate cancer cells in patients who later underwent radical prostatectomy, although each follow-up period was too short to draw any definite survival benefits. Most importantly, it is P-gp substrates such as doxorubicin, Vinca alkaloid, or taxanes that confer cytotoxic effects on prostate cancer cells as chemotherapeutic agents. In turn, these chemotherapeutic agents might be effective for treating high-risk prostate cancer, where P-gp is frequently downregulated through CpG hypermethylation of the MDR1 promoter. Our results suggest that the clinical application of neoadjuvant chemotherapy using P-gp substrates in those prostate cancer patients at higher risk may be beneficial.

In conclusion, CpG hypermethylation of MDR1 promoter is associated with disease progression in prostate cancer via increased cell proliferation activity.

REFERENCES


CpG Hypermethylation of *MDR1* Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer

Hideki Enokida, Hiroaki Shiina, Mikio Igawa, et al.

*Cancer Res* 2004;64:5956-5962.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/17/5956

Cited articles
This article cites 35 articles, 11 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/17/5956.full#ref-list-1

Citing articles
This article has been cited by 14 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/64/17/5956.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.